<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Appl Environ Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Appl Environ Microbiol</journal-id><journal-id journal-id-type="publisher-id">aem</journal-id><journal-title-group><journal-title>Applied and Environmental Microbiology</journal-title></journal-title-group><issn pub-type="ppub">0099-2240</issn><issn pub-type="epub">1098-5336</issn><publisher><publisher-name>American Society for Microbiology</publisher-name><publisher-loc>1752 N St., N.W., Washington, DC</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40243317</article-id><article-id pub-id-type="pmc">PMC12093962</article-id>
<article-id pub-id-type="publisher-id">aem02468-24</article-id><article-id pub-id-type="doi">10.1128/aem.02468-24</article-id><article-id pub-id-type="publisher-id">aem.02468-24</article-id><article-categories><subj-group subj-group-type="heading"><subject>Biotechnology</subject></subj-group><subj-group subj-group-type="biological-terms"><compound-subject><compound-subject-part content-type="code">biotechnology</compound-subject-part><compound-subject-part content-type="label">Biotechnology</compound-subject-part></compound-subject></subj-group></article-categories><title-group><article-title>Modular pathway engineering for enhanced production of <italic toggle="yes">para</italic>-aminobenzoic acid and 4-amino-phenylalanine in <italic toggle="yes">Escherichia coli</italic> via glucose/xylose co-utilization</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nonaka</surname><given-names>Daisuke</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role></contrib><contrib contrib-type="author"><name><surname>Kishida</surname><given-names>Mayumi</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role></contrib><contrib contrib-type="author"><name><surname>Hirata</surname><given-names>Yuuki</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role></contrib><contrib contrib-type="author"><name><surname>Mori</surname><given-names>Ayana</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role></contrib><contrib contrib-type="author"><name><surname>Kondo</surname><given-names>Akihiko</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role></contrib><contrib contrib-type="author"><name><surname>Mori</surname><given-names>Yutaro</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review and editing</role></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5430-1966</contrib-id><name><surname>Noda</surname><given-names>Shuhei</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="cor1" ref-type="corresp"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review and editing</role><email>shuhei.noda@opal.kobe-u.ac.jp</email></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7397-7360</contrib-id><name><surname>Tanaka</surname><given-names>Tsutomu</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor2" ref-type="corresp"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review and editing</role><email>tanaka@kitty.kobe-u.ac.jp</email></contrib><aff id="aff1"><label>1</label><institution-wrap><institution>Department of Chemical Science and Engineering, Graduate School of Engineering, Kobe University</institution><institution-id institution-id-type="Ringgold">542048</institution-id><institution-id institution-id-type="ROR">https://ror.org/01apwkd48</institution-id></institution-wrap>, <city>Kobe</city>, <state>Hyogo</state>, <country>Japan</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution>Graduate School of Science, Technology and Innovation, Kobe University</institution><institution-id institution-id-type="Ringgold">592891</institution-id><institution-id institution-id-type="ROR">https://ror.org/03tgsfw79</institution-id></institution-wrap>, <city>Kobe</city>, <state>Hyogo</state>, <country>Japan</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution>PRESTO, Japan Science and Technology Agency (JST)</institution><institution-id institution-id-type="Ringgold">13501</institution-id><institution-id institution-id-type="ROR">https://ror.org/00097mb19</institution-id></institution-wrap>, <city>Kawaguchi</city>, <state>Saitama</state>, <country>Japan</country></aff></contrib-group><contrib-group><contrib contrib-type="editor"><role>Editor</role><name><surname>Nikel</surname><given-names>Pablo Ivan</given-names></name><aff><institution-wrap><institution>Danmarks Tekniske Universitet The Novo Nordisk Foundation Center for Biosustainability</institution></institution-wrap>, <city>Kgs. Lyngby</city>, <country>Denmark</country></aff></contrib></contrib-group><author-notes><corresp id="cor1">Address correspondence to Shuhei Noda, <email xlink:href="mailto:shuhei.noda@opal.kobe-u.ac.jp">shuhei.noda@opal.kobe-u.ac.jp</email></corresp><corresp id="cor2">Address correspondence to Tsutomu Tanaka, <email xlink:href="mailto:tanaka@kitty.kobe-u.ac.jp">tanaka@kitty.kobe-u.ac.jp</email></corresp><fn fn-type="COI-statement"><p>The authors declare no conflict of interest.</p></fn></author-notes><pub-date publication-format="electronic" date-type="collection"><month>5</month><year>2025</year></pub-date><pub-date date-type="pub" publication-format="electronic"><day>17</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>4</month><year>2025</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>91</volume><issue>5</issue><elocation-id>e02468-24</elocation-id><history>
<date date-type="received"><day>11</day><month>12</month><year>2024</year></date>
<date date-type="accepted"><day>28</day><month>2</month><year>2025</year></date>
</history><permissions><copyright-statement>Copyright &#x000a9; 2025 Nonaka et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Nonaka et al.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2025-04-17"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="aem.02468-24.pdf"/><abstract abstract-type="primary"><title>ABSTRACT</title><p>The modularization of biosynthetic pathways is a promising approach for enhancing microbial chemical production. We have developed a co-utilization method with glucose and xylose substrates to divide metabolic pathways into distinct production and energy modules to enhance the biosynthesis of <italic toggle="yes">para</italic>-aminobenzoic acid (pABA) in <italic toggle="yes">Escherichia coli</italic>. Optimizing initial glucose/xylose concentrations and eliminating carbon leakage resulted in a pABA titer of 8.22 g/L (yield: 0.23 g/g glucose). This strategy was then applied to the biosynthesis of 4APhe, a compound synthesized from chorismate without pyruvate (PYR) release. Utilizing glucose and xylose as co-substrates resulted in the production of 4.90 g/L 4APhe. Although 4APhe production did not benefit from PYR-driven energy generation as pABA production did, high titer was still achieved. This study highlights the effectiveness of modular metabolic pathway division for enhancing the production of key aromatic compounds and provides valuable insight into microbial production of chemicals that require specific biosynthetic donors such as amino groups.</p><sec><title>IMPORTANCE</title><p>Microbial biosynthesis of chemicals from renewable resources offers a sustainable alternative to fossil fuel-based production. However, inefficiencies due to substrate diversion into by-products and biomass hinder optimal yields. In this study, we employed a modular metabolic engineering approach, decoupling pathways for chemical production from cell growth. Using glucose and xylose as co-substrates, we achieved the enhancement of <italic toggle="yes">p</italic>-aminobenzoic acid production in <italic toggle="yes">Escherichia coli</italic>. Additionally, we demonstrated the versatility of this approach by applying it to the biosynthesis of 4-amino-phenylalanine production. This study highlights the potential of modular metabolic pathway division for increased production of target compounds and provides valuable insight into microbial production of chemicals that require specific biosynthetic donors such as amino groups.</p></sec></abstract><kwd-group><title>KEYWORDS</title><kwd>parallel metabolic pathway engineering</kwd><kwd><italic toggle="yes">p</italic>-aminobenzoic acid</kwd><kwd>4-amino-phenylalanine</kwd><kwd>modular metabolic engineering</kwd><kwd><italic toggle="yes">Escherichia coli</italic></kwd></kwd-group><funding-group specific-use="FundRef"><award-group award-type="grant" id="award-1"><funding-source>
<institution-wrap><institution>Japan Society for the Promotion of Science</institution><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id></institution-wrap>
</funding-source><award-id>JP22KJ2279</award-id><principal-award-recipient>
<name><surname>Nonaka</surname><given-names>Daisuke</given-names></name>
</principal-award-recipient></award-group><award-group award-type="grant" id="award-2"><funding-source>
<institution-wrap><institution>Japan Society for the Promotion of Science</institution><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id></institution-wrap>
</funding-source><award-id>JP22H01885</award-id><principal-award-recipient>
<name><surname>Noda</surname><given-names>Shuhei</given-names></name>
</principal-award-recipient></award-group><award-group award-type="grant" id="award-3"><funding-source>
<institution-wrap><institution>Japan Science and Technology Agency</institution><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002241</institution-id></institution-wrap>
</funding-source><award-id>JPMJPR22N9</award-id><principal-award-recipient>
<name><surname>Noda</surname><given-names>Shuhei</given-names></name>
</principal-award-recipient></award-group><award-group award-type="grant" id="award-4"><funding-source>
<institution-wrap><institution>Japan Society for the Promotion of Science</institution><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id></institution-wrap>
</funding-source><award-id>JP23H04565</award-id><principal-award-recipient>
<name><surname>Noda</surname><given-names>Shuhei</given-names></name>
</principal-award-recipient></award-group><award-group award-type="grant" id="award-5"><funding-source>
<institution-wrap><institution>Japan Society for the Promotion of Science</institution><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id></institution-wrap>
</funding-source><award-id>JP22H01880</award-id><principal-award-recipient>
<name><surname>Tanaka</surname><given-names>Tsutomu</given-names></name>
</principal-award-recipient></award-group><award-group award-type="grant" id="award-6"><funding-source>
<institution-wrap><institution>Asahi Glass Foundation</institution><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007684</institution-id></institution-wrap>
</funding-source><principal-award-recipient>
<name><surname>Tanaka</surname><given-names>Tsutomu</given-names></name>
</principal-award-recipient></award-group></funding-group><counts><count count="1" count-type="supplementary-material"/><count count-type="authors" count="8"/><fig-count count="8"/><table-count count="1"/><ref-count count="39"/><page-count count="16"/><word-count count="7322"/></counts><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>INTRODUCTION</title><p><italic toggle="yes">p</italic>-Aminobenzoic acid (pABA) is utilized as a crosslinking agent for resins, as a component in dyes and feedstocks, and as a precursor molecule in the pharmaceutical industry (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). Furthermore, biosynthesis of pABA is a promising alternative supply route for the production of polyethylene terephthalate (PET) and <italic toggle="yes">p</italic>-phenylenediamine (<xref rid="B3" ref-type="bibr">3</xref>). The global demands of both PET and <italic toggle="yes">p</italic>-phenylenediamine are expected to rise in the future; thus, biotechnological production of pABA could represent a vital, sustainable alternative.</p><p>Advances in metabolic engineering and synthetic biology have led to the development of a range of tools and strategies for constructing efficient microbial cell factories (<xref rid="B4" ref-type="bibr">4</xref><xref rid="B5" ref-type="bibr">&#x02013;</xref><xref rid="B8" ref-type="bibr">8</xref>). An engineered strain of <italic toggle="yes">Escherichia coli</italic> with the expression of <italic toggle="yes">pabAB</italic> from <italic toggle="yes">Corynebacterium efficiens</italic> exhibited higher pABA production compared to those with the endogenous <italic toggle="yes">pabAB</italic> (<xref rid="B9" ref-type="bibr">9</xref>). An engineered strain of <italic toggle="yes">C. glutamicum</italic> overexpressing exogenous feedback-resistant aroG<sup>S180F</sup> gene, <italic toggle="yes">pabAB</italic>, and <italic toggle="yes">pabC</italic> produces 6.2 g/L of pABA (<xref rid="B10" ref-type="bibr">10</xref>). Increasing chorismate availability by eliminating the synthetic pathways of aromatic amino acids and partially removing phosphoenolpyruvate (PEP)-consuming pathways has been reported to further increase pABA production in engineered <italic toggle="yes">E. coli</italic>, up to 2.46 g/L of pABA (<xref rid="B11" ref-type="bibr">11</xref>).</p><p>The metabolic burden imposed by genetic or environmental alterations on host cells presents a significant challenge to microbial engineering (<xref rid="B12" ref-type="bibr">12</xref>), often leading to impaired growth and suboptimal metabolic function (<xref rid="B13" ref-type="bibr">13</xref>). The modularization of synthetic pathways has revealed innovative strategies for the systematic optimization of engineered microbial strains. In modular metabolic engineering, enzymes within pathways are organized into distinct, interacting modules to restore metabolic balance and enhance efficiency (<xref rid="B14" ref-type="bibr">14</xref><xref rid="B15" ref-type="bibr">&#x02013;</xref><xref rid="B16" ref-type="bibr">16</xref>). We have previously restructured the native metabolic pathway of <italic toggle="yes">E. coli</italic> to funnel all produced PEP into the biosynthesis of aromatic compounds (<xref rid="B17" ref-type="bibr">17</xref>). The production module consisted of glycolysis and the pentose phosphate pathway and was separated from the energy module at the point of the PEP-to-pyruvate (PYR) conversion. To address the lack of PYR, we further developed a parallel metabolic pathway engineering (PMPE) strategy to restore PYR supply and optimize cell growth (<xref rid="B18" ref-type="bibr">18</xref>). To this end, we engineered a xylose catabolic pathway, which directly integrates with the tricarboxylic acid (TCA) cycle. This circumvents interference with glycolytic and pentose phosphate pathways, allowing glucose to be primarily allocated to the synthesis of desired chemicals, while xylose is utilized to support cell proliferation. The strain that was engineered for PMPE demonstrated significant improvements in production (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>).</p><p>Here, we attempted to enhance pABA production through the co-utilization of glucose and xylose. The pABA biosynthetic pathway releases PYR during its reaction process, using <sc>l</sc>-glutamine (<sc>l</sc>-Gln) as an amino donor. Hence, glucose was utilized as the carbon skeleton for pABA, and xylose was included to support <sc>l</sc>-Gln synthesis and energy generation. (<xref rid="F1" ref-type="fig">Fig. 1</xref>). We evaluated the effects of deleting genes involved in <sc>l</sc>-Gln-consuming pathways on pABA production and finally explored different strategies for xylose supplementation. Our results demonstrate that pABA production can be controlled by adjusting the initial ratio of glucose to xylose. We secondly investigated the potential of our co-utilization strategy for the biosynthesis of 4-amino-phenylalanine (4APhe).</p><fig position="float" fig-type="figure" id="F1"><label>Fig 1</label><caption><p>Metabolic engineering of the <italic toggle="yes">Escherichia coli</italic> strain for production of <italic toggle="yes">p</italic>-aminobenzoic acid (PABA) or 4-amino-phenylalanine (4APhe). Gray crosses indicate deletions of genes in the GX1 strain. 4ADC, 4-amino-4-deoxychorismate; DAHP, 3-deoxy-D-arabino-heptulosonic acid 7-phosphate; E4P, erythrose 4-phosphate; G6P, glucose 6-phosphate; L-Gln, L-glutamine; L-Glu, L-glutamate; L-Phe, L-phenylalanine; L-Tyr, L-tyrosine; PAPP, 4-aminophenylpyruvate; PEP, phosphoenolpyruvate; PP pathway, pentose phosphate pathway.</p></caption><graphic xlink:href="aem.02468-24.f001" position="float"><alt-text>Metabolic pathway depicts xylose and glucose utilization. Xylose catabolism feeds into TCA cycle, while glucose metabolism proceeds via glycolysis and pentose phosphate pathway. Biosynthetic routes for 4APhe and pABA are highlighted.</alt-text></graphic></fig></sec><sec sec-type="materials|methods" id="s2"><title>MATERIALS AND METHODS</title><sec id="s2-1"><title>Strains and plasmid</title><p>The strains used in this study are listed in <xref rid="T1" ref-type="table">Table 1</xref>. We used <italic toggle="yes">E. coli</italic> ATCC31882 as the host strain and <italic toggle="yes">E. coli</italic> NovaBlue competent cells (Novagen, Cambridge, MA, USA) for gene cloning. For polymerase chain reaction (PCR), KOD FX Neo (TOYOBO, Osaka, Japan) was used with DNA primers purchased from Invitrogen Custom DNA Oligos service (Thermo Fisher Scientific, Tokyo, Japan) or DNA Custom Synthesis service (FASMAC, Atsugi, Japan). The plasmids and primers used are listed in <xref rid="SuF1" ref-type="supplementary-material">Tables S1 and S2</xref>. Genes were assembled with the respective plasmids using the NEBuilder HiFi DNA Assembly Master Mix (New England Biolabs, Ipswich, MA, USA). The pT&#x00394;<italic toggle="yes">glsA</italic> plasmid was constructed as follows: the pT&#x00394;glsAF gene fragment was amplified via PCR using pTargetF (<xref rid="B20" ref-type="bibr">20</xref>) as the template and N20_del_glsA_F and N20_del_glsA_R as the primers. The amplified fragment was self-ligated, and the resultant plasmid was named pT&#x00394;glsAF. Upstream and downstream DNA sequences of <italic toggle="yes">glsA</italic> were amplified using <italic toggle="yes">E. coli</italic> MG1655, with Up_del_glsA_F and Up_del_glsA_R, Down_del_glsA_F and Down_del_glsA_R as the respective primer pairs. The resultant fragments were fused using overlap extension PCR with Up_del_glsA_F and Down_del_glsA_R as the primer pair. The amplified donor was cloned into the <italic toggle="yes">EcoR</italic>I/<italic toggle="yes">Sal</italic>I sites of pT&#x00394;glsAF, resulting in the production of the pT&#x00394;<italic toggle="yes">glsA</italic> plasmid. Other plasmids of the pTarget series&#x02014;namely pT&#x00394;<italic toggle="yes">glsB</italic>, pT&#x00394;<italic toggle="yes">glnB</italic>, pT&#x00394;<italic toggle="yes">glnE</italic>, pT&#x00394;<italic toggle="yes">carAB</italic>, and pT&#x00394;<italic toggle="yes">xylAB</italic>&#x02014;were constructed using the same procedure as for pT&#x00394;<italic toggle="yes">glsA</italic>. The CRISPR-Cas9 two-plasmid system was used for genetic deletions in the engineered strain with the pTarget and pCas plasmids (<xref rid="B20" ref-type="bibr">20</xref>).</p><table-wrap position="float" id="T1"><label>TABLE 1</label><caption><p>Strains used in the present study</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" colspan="1" rowspan="1">Strain</th><th align="left" valign="top" colspan="1" rowspan="1">Genotype</th><th align="left" valign="top" colspan="1" rowspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">Nova Blue</td><td align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">endA1</italic>, <italic toggle="yes">hsdR17</italic> (r<sub>K</sub>
<sup>&#x02212;</sup>m<sub>K</sub>
<sup>+)</sup>, <italic toggle="yes">supE44 thi-I</italic>, gyrA96<italic toggle="yes">, relA1</italic>, <italic toggle="yes">lac</italic>, <italic toggle="yes">recA1/</italic>F [<italic toggle="yes">proAB<sup>+</sup></italic>, <italic toggle="yes">lacI</italic>qZ&#x00394;M15, Tn10(Tet R)]</td><td align="left" valign="top" colspan="1" rowspan="1">Novagen</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">ATCC31882</td><td align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">aroF aroG tyrR pheA pheA</italic>o <italic toggle="yes">tyrA trpE</italic> (derived from <italic toggle="yes">Escherichia coli</italic> K12)</td><td align="left" valign="top" colspan="1" rowspan="1">ATCC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">GX1</td><td align="left" valign="top" colspan="1" rowspan="1">ATCC31882 <italic toggle="yes">ptsHI</italic>::P<sub>A1lacO-1</sub>-<italic toggle="yes">glk-galP</italic> &#x00394;<italic toggle="yes">pykF</italic> &#x00394;<italic toggle="yes">pykA</italic> &#x00394;<italic toggle="yes">pheA</italic> &#x00394;<italic toggle="yes">tyrA</italic> &#x00394;<italic toggle="yes">eda</italic> &#x00394;<italic toggle="yes">ppc</italic> &#x00394;<italic toggle="yes">pck</italic> &#x00394;<italic toggle="yes">ppsA</italic></td><td align="left" valign="top" colspan="1" rowspan="1">(<xref rid="B18" ref-type="bibr">18</xref>)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">CFT037</td><td align="left" valign="top" colspan="1" rowspan="1">ATCC31882 <italic toggle="yes">ptsHI</italic>::P<sub>A1lacO-1</sub>-<italic toggle="yes">glk-galP</italic> &#x00394;<italic toggle="yes">pykF</italic> &#x00394;<italic toggle="yes">pykA</italic> &#x00394;<italic toggle="yes">eda</italic> &#x00394;<italic toggle="yes">ppc</italic> &#x00394;<italic toggle="yes">pck</italic> &#x00394;<italic toggle="yes">ppsA</italic>&#x00394;<italic toggle="yes">edd</italic>&#x00394;<italic toggle="yes">iclR</italic>&#x00394;<italic toggle="yes">sdaA</italic></td><td align="left" valign="top" colspan="1" rowspan="1">(<xref rid="B17" ref-type="bibr">17</xref>)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">GX11</td><td align="left" valign="top" colspan="1" rowspan="1">GX1&#x00394;<italic toggle="yes">glsA</italic>&#x00394;<italic toggle="yes">glsB</italic></td><td align="left" valign="top" colspan="1" rowspan="1">This study</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">GX12</td><td align="left" valign="top" colspan="1" rowspan="1">GX1&#x00394;<italic toggle="yes">glnB</italic>&#x00394;<italic toggle="yes">glnE</italic></td><td align="left" valign="top" colspan="1" rowspan="1">This study</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">GX13</td><td align="left" valign="top" colspan="1" rowspan="1">GX1&#x00394;<italic toggle="yes">carAB</italic></td><td align="left" valign="top" colspan="1" rowspan="1">This study</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">GX14</td><td align="left" valign="top" colspan="1" rowspan="1">GX1&#x00394;<italic toggle="yes">glsA</italic>&#x00394;<italic toggle="yes">glsB</italic>&#x00394;<italic toggle="yes">carAB</italic></td><td align="left" valign="top" colspan="1" rowspan="1">This study</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">GX15</td><td align="left" valign="top" colspan="1" rowspan="1">GX1&#x00394;<italic toggle="yes">glsA</italic>&#x00394;<italic toggle="yes">glsB</italic>&#x00394;<italic toggle="yes">glnB</italic>&#x00394;<italic toggle="yes">glnE</italic>&#x00394;<italic toggle="yes">carAB</italic></td><td align="left" valign="top" colspan="1" rowspan="1">This study</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">GX16</td><td align="left" valign="top" colspan="1" rowspan="1">CFT037&#x00394;<italic toggle="yes">sdaB</italic>&#x00394;<italic toggle="yes">tdcG</italic>&#x00394;<italic toggle="yes">xylAB</italic>&#x00394;<italic toggle="yes">pheA</italic> &#x00394;<italic toggle="yes">tyrA</italic></td><td align="left" valign="top" colspan="1" rowspan="1">This study</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">GX17</td><td align="left" valign="top" colspan="1" rowspan="1">GX16&#x00394;<italic toggle="yes">nhoA</italic></td><td align="left" valign="top" colspan="1" rowspan="1">This study</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">GX1B</td><td align="left" valign="top" colspan="1" rowspan="1">GX1 harboring pZE12-<italic toggle="yes">pabABC</italic></td><td align="left" valign="top" colspan="1" rowspan="1">This study</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">GX1BD</td><td align="left" valign="top" colspan="1" rowspan="1">GX1B harboring pSAK-D2 plasmid</td><td align="left" valign="top" colspan="1" rowspan="1">This study</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">GX1BW</td><td align="left" valign="top" colspan="1" rowspan="1">GX1B harboring pSAK-W plasmid</td><td align="left" valign="top" colspan="1" rowspan="1">This study</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">GX11BW</td><td align="left" valign="top" colspan="1" rowspan="1">GX11 harboring pZE12-<italic toggle="yes">pabABC</italic> and pSAK-W plasmids</td><td align="left" valign="top" colspan="1" rowspan="1">This study</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">GX12BW</td><td align="left" valign="top" colspan="1" rowspan="1">GX12 harboring pZE12-<italic toggle="yes">pabABC</italic> and pSAK-W plasmids</td><td align="left" valign="top" colspan="1" rowspan="1">This study</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">GX13BW</td><td align="left" valign="top" colspan="1" rowspan="1">GX13 harboring pZE12-<italic toggle="yes">pabABC</italic> and pSAK-W plasmids</td><td align="left" valign="top" colspan="1" rowspan="1">This study</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">GX14BW</td><td align="left" valign="top" colspan="1" rowspan="1">GX14 harboring pZE12-<italic toggle="yes">pabABC</italic> and pSAK-W plasmids</td><td align="left" valign="top" colspan="1" rowspan="1">This study</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">GX15BW</td><td align="left" valign="top" colspan="1" rowspan="1">GX15 harboring pZE12-<italic toggle="yes">pabABC</italic> and pSAK-W plasmids</td><td align="left" valign="top" colspan="1" rowspan="1">This study</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">GX16BW</td><td align="left" valign="top" colspan="1" rowspan="1">GX16 harboring pZE12-<italic toggle="yes">pabABC</italic> and pSAK-W plasmids</td><td align="left" valign="top" colspan="1" rowspan="1">This study</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">GX17BW</td><td align="left" valign="top" colspan="1" rowspan="1">GX17 harboring pZE12-<italic toggle="yes">pabABC</italic> and pSAK-W plasmids</td><td align="left" valign="top" colspan="1" rowspan="1">This study</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">GX16AW</td><td align="left" valign="top" colspan="1" rowspan="1">GX16 harboring pNE-Ptrc-EcpabAB-SvpapBC and pSAK-W plasmids</td><td align="left" valign="top" colspan="1" rowspan="1">This study</td></tr></tbody></table></table-wrap></sec><sec id="s2-2"><title>Media</title><p>Lysogeny broth (LB) medium comprised the following (per liter): 10 g tryptone, 5 g yeast extract, and 5 g NaCl. The recipe for M9Y medium used was: glucose and xylose at various appropriate concentrations, 5 g/L of yeast extract, 0.1 mM CaCl<sub>2</sub>&#x0ff65;2H<sub>2</sub>O, 0.01 mM FeSO<sub>4</sub>&#x0ff65;7H<sub>2</sub>O, 1 mM MgSO<sub>4</sub>&#x0ff65;7H<sub>2</sub>O, 10 mg/L of thiamine hydrochloride, 0.5 g/L of NaCl, 6.7 g/L of Na<sub>2</sub>HPO<sub>4</sub>, 3 g/L of KH<sub>2</sub>PO<sub>4</sub>, 1 g/L of NH<sub>4</sub>Cl, and 0.1 mM IPTG, 40 mg/L <sc>l</sc>-tyrosine, 40 mg/L <sc>l</sc>-tryptophan, and 100 mg/L <sc>l</sc>-phenylalanine. Ampicillin and/or chloramphenicol were added to final concentrations of 100 and 30 mg/L, respectively, where appropriate.</p><p>Modified M9Y medium [15 g/L glucose and 5 g/L xylose, 10 mM &#x003b1;-ketoglutarate, 5 g/L yeast extract, 100 mg/L <sc>l</sc>-tyrosine, 100 mg/L <sc>l</sc>-tryptophan, 100 mg/L <sc>l</sc>-phenylalanine, 6 g/L Na<sub>2</sub>HPO<sub>4</sub>, 3 g/L KH<sub>2</sub>PO<sub>4</sub>, 0.5 g/L NaCl, 2 g/L (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 0.1 mM CaCl<sub>2</sub>&#x0ff65;2H<sub>2</sub>O, 0.01 mM FeSO<sub>4</sub>&#x0ff65;7H<sub>2</sub>O, 1 mM MgSO<sub>4</sub>&#x0ff65;7H<sub>2</sub>O, 10 mg/L of thiamine hydrochloride, 0.1 mM IPTG, 100 mg/L ampicillin, and 30 mg/L chloramphenicol] was used for bioreactor cultivation. When cultivating GX17BW, glucose/MgSO<sub>4</sub> rich medium (30 g/L glucose and 10 mM MgSO<sub>4</sub>&#x0ff65;7H<sub>2</sub>O) was used.</p><p>The feeding medium for fed-batch cultivation of pABA was composed of 600 g/L glucose, 200 g/L xylose, 8 g/L MgSO<sub>4</sub>&#x0ff65;7H<sub>2</sub>O, 100 mg/L <sc>l</sc>-tyrosine, 100 mg/L <sc>l</sc>-tryptophan, 100 mg/L <sc>l</sc>-phenylalanine, 0.1 mM CaCl<sub>2</sub>&#x0ff65;2H<sub>2</sub>O, 0.01 mM FeSO<sub>4</sub>&#x0ff65;7H<sub>2</sub>O, and 10 mg/L of thiamine hydrochloride, 1 mM IPTG, 100 mg/L ampicillin, and 30 mg/L chloramphenicol. When cultivating GX17BW, the feeding medium was as follows: 100 g/L xylose and 200 mg/L ampicillin.</p><p>The feed solution for 4APhe production was as follows: 500 g/L glucose, 250 g/L xylose, 8 g/L MgSO<sub>4</sub>&#x0ff65;7H<sub>2</sub>O, 100 mg/L <sc>l</sc>-tyrosine, 100 mg/L <sc>l</sc>-tryptophan, 100 mg/L <sc>l</sc>-phenylalanine, 0.1 mM CaCl<sub>2</sub>&#x0ff65;2H<sub>2</sub>O, 0.01 mM FeSO<sub>4</sub>&#x0ff65;7H<sub>2</sub>O, 10 mg/L of thiamine hydrochloride, 1 mM IPTG, 200 mg/L ampicillin, and 30 mg/L chloramphenicol.</p></sec><sec id="s2-3"><title>Culture conditions</title><p>Engineered strains were inoculated into 4 mL of M9Y medium in a 15 mL test tube and incubated overnight at 37&#x000b0;C with shaking at 220 rpm. For microbial production, this pre-culture was transferred into a 15 mL test tube containing 5 mL of M9Y medium at an initial optical density (OD)<sub>600</sub> of 0.1. The test tubes were incubated at 37&#x000b0;C with shaking at 220 rpm.</p><p>In the case of bioreactor cultivation, engineered strains were inoculated in 50 mL of M9Y medium containing 20 g/L glucose and 20 g/L xylose and incubated overnight at 37&#x000b0;C with shaking at 220 rpm in a 200 mL flask. Pre-cultures were transferred into a 1 L bioreactor containing 600 mL of modified M9Y medium until the OD<sub>600</sub> reached 0.1. The temperature and pH were maintained at 30&#x000b0;C and 7.00. The pH was controlled by automated addition of 28% (vol/vol) NH<sub>3</sub> and 1 N H<sub>2</sub>SO<sub>4.</sub> PLONON 201 (NOF CORPORATION, Tokyo, Japan) was included to prevent foam formation. Dissolved oxygen (DO) was maintained at 30% by controlling agitation. For the cultivation of the GX16BW strain and GX16AW strain (Fig. 6A through D), the feeding solution was added at the rate of 1 mL/min when the DO level increased over 31.2%, and the feeding was automatically stopped when the DO decreased back to 30%. For the cultivation of the GX17BW strain (Fig. 6E through H), the feeding solution (10 mL) was manually added after 47, 71, and 96 h.</p></sec><sec id="s2-4"><title>Analytical methods</title><p>Cell growth was determined by measuring the OD<sub>600</sub> using a UVmini-1240 spectrophotometer (Shimadzu Corporation, Kyoto, Japan). Sugars (glucose and xylose) were analyzed using a Prominence HPLC System (Shimadzu) equipped with a Shodex SUGAR KS-801 column (grain diameter: 6 &#x000b5;m, <italic toggle="yes">L</italic> &#x000d7; I.D.: 300 &#x000d7; 8.0 mm<sup>2</sup>; Resonac Holdings Corporation, Tokyo, Japan). The mobile phase was water, run at a rate of 0.8 mL/min at 60&#x000b0;C. The high-performance liquid chromatography (HPLC) profile was detected using a refractive index detector.</p><p>We used an HPLC (Shimadzu Corporation) equipped with an MSII column (5 &#x000b5;m, 4.6 mm, I.D. &#x000d7; 250 mm L) (Nacalai Tesque, Kyoto, Japan) for pABA analysis and obtained elution profiles using a 254 nm UV-VIS detector. The two-component system was used with a mobile phase of 0.2% phosphate buffer (A) and methanol (B). The gradient was started with a 70:30 mixture of A and B, shifting to a 50:50 mixture over 2 min beginning at 4 min. This ratio was retained from 6 to 14 min, then returned to the 70:30 ratio by 16 min (over the course of 2 min). The flow rate of the mobile phase was 1.0 mL/min, and the column remained at 40&#x000b0;C.</p><p>Samples for 4APhe analysis were labeled using the DL-Amino Acid Labeling Kit (Nacalai Tesque), according to the manufacturer&#x02019;s instructions. Each sample was analyzed using an HPLC (Shimadzu Corporation) equipped with an MSII column (5 &#x000b5;m, 4.6 mm I.D. &#x000d7; 250 mm L, Nacalai Tesque), and profiles were obtained using a 340 nm UV-VIS detector. The two-component system was used with a mobile phase of 0.2% phosphate buffer (A) and methanol (B). The ratio of the two mobile phase solutions was kept at 50:50. The flow rate of the mobile phase was 1.0 mL/min for 20 min, and the column remained at 40&#x000b0;C.</p></sec></sec><sec sec-type="results|discussion" id="s3"><title>RESULTS AND DISCUSSION</title><sec id="s3-1"><title>Construction of pABA-producing strain using glucose and xylose as co-substrate</title><p><italic toggle="yes">E. coli</italic> strain GX1 (<xref rid="B18" ref-type="bibr">18</xref>), which is derived from ATCC31882 (a phenylalanine overproducer), was used as a host strain for pABA production (<xref rid="F1" ref-type="fig">Fig. 1</xref>). This strain lacks the <italic toggle="yes">pykF</italic>, <italic toggle="yes">pykA</italic>, <italic toggle="yes">eda</italic>, <italic toggle="yes">ppc</italic>, <italic toggle="yes">pck</italic>, and <italic toggle="yes">ppsA</italic> genes and is suitable for the synthesis of shikimate pathway derivatives. The phosphotransferase system was previously replaced with the galactose permease system to block conversion of PEP to PYR. Consequently, the metabolic pathway in the GX1 strain was successfully engineered to promote PEP accumulation. The Dahms pathway converts xylose into glyoxylate and PYR, and so was introduced to restore the PYR supply. This strain was then able to utilize glucose to produce only shikimate derivative, and xylose was used solely for cell growth. This strain was applicable for pABA production as pABA is synthesized from chorismate.</p><p>pABA can be also produced in bacteria and yeasts via the shikimate pathway. PEP is produced in glycolysis, and erythrose 4-phosphate is formed in the pentose phosphate pathway, and the condensation of the compounds produces 3-deoxy-<sc>d</sc>-arabino-heptulosonate 7-phosphate (DAHP). The DAHP is subsequently converted to chorismate. The biosynthesis of pABA from chorismate involves two conversion steps, which are catalyzed by three enzymes via the intermediate 4-amino-4-deoxychorismate (4ADC). In the first step, ADC synthase component II and ADC synthase component I, which are encoded by <italic toggle="yes">pabA</italic> and <italic toggle="yes">pabB</italic>, respectively, substitute the hydroxyl group at position 4 of chorismate with an amino group using glutamine. In the second step, ADC lyase (encoded by <italic toggle="yes">pabC</italic>) eliminates PYR, forming pABA (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>).</p><p>We used the pZE12-<italic toggle="yes">pabABC</italic> (<xref rid="B23" ref-type="bibr">23</xref>) plasmid&#x02014;which contains the <italic toggle="yes">pabA</italic>, <italic toggle="yes">pabB</italic>, and <italic toggle="yes">pabC</italic> genes&#x02014;to produce pABA from glucose. PYR is released in the final step catalyzed by the product of <italic toggle="yes">pabC</italic>; thus, the GX1B strain (GX1 harboring pZE12-<italic toggle="yes">pabABC</italic>) was anticipated to use glucose as its sole carbon source, as in salicylate synthesis (<xref rid="B17" ref-type="bibr">17</xref>). However, we did not observe significant growth when glucose was provided as the sole carbon source (<xref rid="F2" ref-type="fig">Fig. 2A</xref>), and the amount of pABA produced was less than 0.2 g/L (<xref rid="F2" ref-type="fig">Fig. 2B</xref>). To promote the TCA cycle, we introduced the Dahms pathway from <italic toggle="yes">Caulobacter crescentus</italic> as this involves the conversion of xylose to <sc>d</sc>-xylonolactone by xylose dehydrogenase (XDH), enabling the use of xylose as a carbon source. After nonenzymatic transformation or the reaction catalyzed by xylonolactonase of <sc>d</sc>-xylonolactone to <sc>d</sc>-xylonate, endogenous xylonate dehydratases (YjhG) of <italic toggle="yes">E. coli</italic> convert <sc>d</sc>-xylonate to 2-keto-3-deoxy-<sc>d</sc>-xylonate. Endogenous aldolases (YjhH) catalyze the conversion of this chemical to glycoaldehyde and PYR. Glycoaldehyde is then metabolized as glycolate through endogenous metabolic activity in <italic toggle="yes">E. coli</italic>, and glycolate is subsequently converted to malate by glyoxylate shunt (<xref rid="F1" ref-type="fig">Fig. 1</xref>) (<xref rid="B24" ref-type="bibr">24</xref>).</p><fig position="float" fig-type="figure" id="F2"><label>Fig 2</label><caption><p>Culture profiles of the GX1B, GX1BD, and GX1BW strains. Each strain included the pZE12-<italic toggle="yes">pabABC</italic> plasmid and either pSAK-D2 or pSAK-W plasmids and were cultivated in M9Y medium. The GX1B strain was grown in 20 g/L glucose, while the GX1BD and GX1BW strains were cultivated in a medium containing 20 g/L each of glucose and xylose. The graphs illustrate (A) cell growth, (B) <italic toggle="yes">p</italic>-aminobenzoic acid concentration, (C) glucose concentration, and (D) xylose concentration. Data are presented as means, and error bars indicate the standard deviation from three independent experiments.</p></caption><graphic xlink:href="aem.02468-24.f002" position="float"><alt-text>Growth and metabolic profiles of GX1B, GX1BD, and GX1BW strains. OD&#x02086;&#x02080;&#x02080; increases over time, with GX1BW depicting highest pABA production. Glucose and xylose consumption rates vary across strains, with GX1BW utilizing most substrate.</alt-text></graphic></fig><p>We introduced the pSAK-D2 plasmid containing <italic toggle="yes">xylB</italic> and <italic toggle="yes">xylC</italic> from <italic toggle="yes">C. crescentus</italic>, <italic toggle="yes">yjhHG</italic> from <italic toggle="yes">E. coli</italic> (<xref rid="B19" ref-type="bibr">19</xref>) into the GX1B strain, resulting in the GX1BD strain. After 48 h of cultivation in a medium containing glucose/xylose as co-substrates, 0.55 &#x000b1; 0.01 g/L pABA was produced (<xref rid="F2" ref-type="fig">Fig. 2B</xref>). However, both GX1B and GX1BD strains showed poor growth (<xref rid="F2" ref-type="fig">Fig. 2A</xref>), with GX1BD consuming 4.44 g/L of glucose (<xref rid="F2" ref-type="fig">Fig. 2C</xref>). In the pABA biosynthetic pathway, &#x003b1;-ketoglutarate (&#x003b1;-KG) is an intermediate in the synthesis of the amino donor <sc>l</sc>-Gln. To address this limitation, we considered the Weimberg pathway as an alternative to the Dahms pathway. In the Weimberg pathway, XDH converts <sc>d</sc>-xylose to <sc>d</sc>-xylonolactone, which is then converted to &#x003b1;-KG via <sc>d</sc>-xylonate, 2-keto-3-deoxy-<sc>d</sc>-xylonate, and 2-oxoglutarate semialdehyde. We then introduced pSAK-W (<xref rid="B19" ref-type="bibr">19</xref>) into GX1B, generating the GX1BW strain, which produced 1.27 &#x000b1; 0.07 g/L pABA in the same culture conditions (<xref rid="F2" ref-type="fig">Fig. 2B</xref>), significantly higher than GX1BD. Additionally, cell growth was markedly improved, with GX1BW consuming 5.21 g/L of glucose and 6.44 g/L of xylose (<xref rid="F2" ref-type="fig">Fig. 2A, C and D</xref>). The yield of pABA in GX1BW was 0.24 g/g-glucose; a twofold increase compared to our previous report (0.12 g/g-glucose [<xref rid="B11" ref-type="bibr">11</xref>]). These results indicate that manipulating metabolic pathways related to <sc>l</sc>-Gln synthesis impacts pABA production.</p></sec><sec id="s3-2"><title>Deletions of genes for improving <sc>l</sc>-Gln availability</title><p>We evaluated the effect of <sc>l</sc>-Gln on pABA production in GX1BW. Cultivation of GX1BW in M9Y broth containing 20 g/L each of glucose and xylose, supplemented with 1 mM or 5 mM <sc>l</sc>-Gln, revealed that <sc>l</sc>-Gln improved cell growth and sugar consumption rate (<xref rid="F3" ref-type="fig">Fig. 3A and C</xref>). After 48 h of cultivation, the titer of pABA was slightly increased with the 5 mM of <sc>l</sc>-Gln supplement (<xref rid="F3" ref-type="fig">Fig. 3B</xref>), indicating that <sc>l</sc>-Gln replenishes the slight depletion of substrates around the TCA cycle and improving the supply of <sc>l</sc>-Gln in GX1BW can increase pABA titer.</p><fig position="float" fig-type="figure" id="F3"><label>Fig 3</label><caption><p>Culture profiles of GX1BW strains. The cell strains contained the pSAK-W and pZE12-<italic toggle="yes">pabABC</italic> plasmids and were cultured in M9Y medium containing glucose and xylose with the addition of <sc>l</sc>-glutamine. Graphs illustrate (A) cell growth, (B) <italic toggle="yes">para</italic>-aminobenzoic acid concentration, (C) glucose concentration, and (D) pABA titers from GX11BW-GX15BW strains with the pSAK-W and pZE12-<italic toggle="yes">pabABC</italic> plasmids grown in M9Y medium containing 20 g/L each of glucose and xylose. Data are presented as means, and error bars indicate the standard deviation from three independent experiments. *<italic toggle="yes">P</italic> &#x0003c; 0.05, compared to the GX1BW strain.</p></caption><graphic xlink:href="aem.02468-24.f003" position="float"><alt-text>Growth and metabolic analysis under different conditions. Higher supplementation enhances OD&#x02086;&#x02080;&#x02080;, pABA production, and glucose consumption. Bar graph compares pABA levels across strains and treatments, depicting significant variation.</alt-text></graphic></fig><p>To improve <sc>l</sc>-Gln availability for pABA synthesis, we disrupted three specific pathways in the GX1 strain: <italic toggle="yes">glsAB</italic>, <italic toggle="yes">glnBE</italic>, and <italic toggle="yes">carAB</italic>. The <italic toggle="yes">glsA</italic> and <italic toggle="yes">glsB</italic> genes encode glutaminases (GlsA and GlsB), which catalyze the reverse reaction of <sc>l</sc>-Gln synthesis. The <italic toggle="yes">glnB</italic> and <italic toggle="yes">glnE</italic> genes encode PII-1 protein and glutamine synthetase adenylyltransferase/deadenylase, respectively, which diminish glutamine synthetase (encoded by <italic toggle="yes">glnA</italic>) activity involved in <sc>l</sc>-Gln production. Finally, <italic toggle="yes">carA</italic> and <italic toggle="yes">carB</italic> encode carbamoyl-phosphate synthase subunits involved in the synthesis of citrulline and arginine. A previous study demonstrated that the deletion of <italic toggle="yes">glnB</italic> and <italic toggle="yes">glnE</italic> improves <sc>l</sc>-Gln production by 24.1% (<xref rid="B25" ref-type="bibr">25</xref>). Knockout of the <italic toggle="yes">glsA</italic>, <italic toggle="yes">glsB</italic>, <italic toggle="yes">glnB</italic>, <italic toggle="yes">glnE</italic>, and <italic toggle="yes">lpxM</italic> genes resulted in the production of more than twice as much <sc>l</sc>-Gln compared to the control. We constructed the GX1&#x00394;<italic toggle="yes">glsAB</italic>, GX1&#x00394;<italic toggle="yes">glnBE</italic>, and GX1&#x00394;<italic toggle="yes">carAB</italic> strains and introduced both pZE12-<italic toggle="yes">pabABC</italic> and pSAK<italic toggle="yes">-</italic>W plasmids into these strains, resulting in GX11BW, GX12BW, and GX13BW strains. After 48 h of cultivation, the GX11BW, GX12BW, and GX13BW strains produced 1.18 &#x000b1; 0.01, 1.22 &#x000b1; 0.01, and 1.26 &#x000b1; 0.01 g/L pABA, respectively (<xref rid="F3" ref-type="fig">Fig. 3D</xref>). Disruption of <italic toggle="yes">glsAB</italic> and <italic toggle="yes">carAB</italic> in GX1 resulted in the GX14 strain. GX14BW harboring pZE12-<italic toggle="yes">pabABC</italic> and pSAK<italic toggle="yes">-</italic>W plasmids produced 1.22 &#x000b1; 0.05 g/L pABA. Additional disruption of <italic toggle="yes">glnB</italic> and <italic toggle="yes">glnE</italic> in GX14, resulting in the GX15BW strain, produced 1.02 &#x000b1; 0.01 g/L pABA from glucose. Combinatorial disruption of the three pathways did not improve pABA titer from glucose. These results indicate that improving the efficacy of <sc>l</sc>-Gln utilization is not effective for increasing pABA production.</p></sec><sec id="s3-3"><title>Control of pABA production by optimization of glucose/xylose ratio and eliminating carbon leakage</title><p>Optimizing the ratio of supplied glucose to xylose was a potential avenue for further improvement of pABA production. For this, we cultivated the GX1BW strain in M9Y medium containing both glucose and xylose as follows: 15 g/L glucose and 5 g/L xylose, 10 g/L each glucose and xylose, and 5 g/L glucose and 15 g/L xylose. There was no significant difference in pABA production, cell growth, or glucose uptake in these conditions (<xref rid="F4" ref-type="fig">Fig. 4A through C</xref>). However, the higher initial concentration of xylose led to more rapid xylose uptake (<xref rid="F4" ref-type="fig">Fig. 4D</xref>), suggesting that the endogenous xylose isomerase pathway in <italic toggle="yes">E. coli</italic> might have been activated.</p><fig position="float" fig-type="figure" id="F4"><label>Fig 4</label><caption><p>Culture profiles of the GX1BW strain cultured in M9Y medium containing 15 g/L glucose and 5 g/L xylose (light green circles), 10 g/L glucose and 10 g/L xylose (green squares), or 5 g/L glucose and 15 g/L xylose (dark green crosses). Graphs illustrate (A) cell growth, (B) <italic toggle="yes">para</italic>-aminobenzoic acid concentration, (C) glucose concentration, and (D) xylose concentration. Data are presented as means, and error bars indicate the standard deviation from three independent experiments.</p></caption><graphic xlink:href="aem.02468-24.f004" position="float"><alt-text>Growth and metabolic trends over 48 hours. OD&#x02086;&#x02080;&#x02080; and pABA concentration increase over time. Glucose and xylose consumption rates vary, with higher substrate utilization correlating with greater pABA production.</alt-text></graphic></fig><p>Due to the complexity of the PEP and PYR-related pathways, controlling these pathways represents a key challenge for shikimate-pathway-derived compound biosynthesis. One effective approach to overcome this challenge is the inactivation of serine deamination mediated by <sc>l</sc>-serine deaminase (LSD). There are three isozymes of LSD in <italic toggle="yes">E. coli</italic>: LSD1, LSD2, and LSD3, encoded by <italic toggle="yes">sdaA</italic>, <italic toggle="yes">sdaB</italic>, and <italic toggle="yes">tdcG</italic>, respectively. While <italic toggle="yes">sdaA</italic> is active under anaerobic conditions in rich media (<xref rid="B26" ref-type="bibr">26</xref>), <italic toggle="yes">sdaB</italic> and <italic toggle="yes">tdcG</italic> are activated in glucose-limited conditions (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>). Interestingly, all three LSDs are active under aerobic, glucose-rich conditions during maleate production (<xref rid="B17" ref-type="bibr">17</xref>).</p><p>To fully decouple the pABA biosynthetic pathway from those involved in cell growth, we disrupted both the xylose isomerase and serine deamination pathways. We constructed a GX16 strain by disrupting the <italic toggle="yes">sdaB</italic>, <italic toggle="yes">tdcG</italic>, and <italic toggle="yes">xylAB</italic> genes in the CFT037 strain (<xref rid="B17" ref-type="bibr">17</xref>) and cultivated the GX16BW strain, which contained the pZE12-<italic toggle="yes">pabABC</italic> and pSAK-W plasmids, in M9Y broth containing glucose and xylose. Disrupting the serine deamination and xylose isomerase pathways resulted in increased pABA titer (<xref rid="F5" ref-type="fig">Fig. 5B</xref>). After 72 h of cultivation in M9Y broth containing 15 g/L glucose and 5 g/L xylose, the GX16BW strain produced 2.38 &#x000b1; 0.04 g/L pABA, with a yield of 0.20 &#x000b1; 0.01 g/g from glucose. Additionally, the consumption of both glucose and xylose was increased compared to the GX1BW strain (<xref rid="F5" ref-type="fig">Fig. 5C and D</xref>). Increased glucose consumption was directly correlated with higher pABA production, indicating that enhanced glucose utilization contributes to improved pABA titer. This aligns with previous studies on the CFT591 strain, which lacks any LSD enzymes and exhibits improved cell growth and glucose consumption (<xref rid="B17" ref-type="bibr">17</xref>). Additionally, increased xylose uptake following disruption of <italic toggle="yes">xylAB</italic> suggests that the GX16BW utilizes xylose through an exogenous xylose assimilation pathway (the Weimberg pathway). This highlights the feasibility of controlling pABA production by regulating xylose consumption to drive the TCA cycle and production of the amino donor.</p><fig position="float" fig-type="figure" id="F5"><label>Fig 5</label><caption><p>Culture profiles of the GX16BW strain cultured in M9Y medium containing 15 g/L glucose and 5 g/L xylose (light green circles), 10 g/L glucose and 10 g/L xylose (green squares), or 5 g/L glucose and 15 g/L xylose (dark green crosses). Graphs illustrate (A) cell growth, (B) <italic toggle="yes">para</italic>-aminobenzoic acid concentration, (C) glucose concentration, and (D) xylose concentration. (E) The comparison of pABA production between GX1BW and GX16BW strains in M9Y medium containing 15 g/L glucose and 5 g/L xylose as carbon sources. Data are presented as means, and error bars indicate the standard deviation from three independent experiments. *<italic toggle="yes">P</italic> &#x0003c; 0.05, compared to the GX1BW strain.</p></caption><graphic xlink:href="aem.02468-24.f005" position="float"><alt-text>Growth and metabolic profiles over 72 hours. OD&#x02086;&#x02080;&#x02080; and pABA production increase, with GX16BW producing more pABA than GX1BW. Glucose and xylose consumption correlate with production. Statistical significance is indicated.</alt-text></graphic></fig></sec><sec id="s3-4"><title>Fed-batch cultivation for pABA production using glucose/xylose as co-substrates</title><p>We cultivated the GX16BW strain to further enhance pABA production using fed-batch fermentation in a 1 L bioreactor. After 121 h of cultivation with a glucose-xylose co-substrate, the strain produced 3.13 g/L of pABA (<xref rid="F6" ref-type="fig">Fig. 6A through C</xref>). However, rapid accumulation of 4-acetamidobenzoic acid was observed after 72 h of cultivation (<xref rid="F6" ref-type="fig">Fig. 6D</xref>), which coincided with the cessation of further increase in pABA production (<xref rid="F6" ref-type="fig">Fig. 6B</xref>). By the end of cultivation, 1.91 g/L 4-acetamidobenzoic acid had accumulated (<xref rid="F6" ref-type="fig">Fig. 6D</xref>). Arylamine N-acetyltransferase (encoded by <italic toggle="yes">nhoA</italic>) has been reported to convert pABA to 4-acetamidobenzoic acid by acetylation (<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>). Considering that this undesirable side reaction might accelerate pABA acetylation during the later stages of cultivation, we disrupted the <italic toggle="yes">nhoA</italic> gene in GX16 to generate GX17. Unexpectedly, the GX17BW strain harboring the pZE12-<italic toggle="yes">pabABC</italic> and pSAK-W plasmids continued to accumulate 4-acetamidobenzoic acid despite the absence of the <italic toggle="yes">nhoA</italic> gene (<xref rid="SuF1" ref-type="supplementary-material">Fig. S1</xref>). This observation suggests that other factors besides <italic toggle="yes">nhoA</italic> expression may contribute to pABA acetylation. For example, nonenzymatic acetylation of lysine residues occurs primarily during the stationary phase and involves acetyl-phosphate (<xref rid="B31" ref-type="bibr">31</xref><xref rid="B32" ref-type="bibr">&#x02013;</xref><xref rid="B33" ref-type="bibr">33</xref>). It is plausible that a similar nonenzymatic mechanism is responsible for pABA acetylation during the stationary phase. Acetyl-CoA availability has been found to improve during sulfur or magnesium starvation when <italic toggle="yes">E. coli</italic> is cultivated with low glucose concentrations (<xref rid="B34" ref-type="bibr">34</xref>). Based on this, we cultivated the GX17BW strain in both glucose- and MgSO<sub>4</sub>-rich medium. After 118 h of cultivation, 8.22 g/L pABA was produced (<xref rid="F6" ref-type="fig">Fig. 6E through G</xref>), equivalent to a yield of 0.23 g/g glucose, which is the highest reported level of pABA production in <italic toggle="yes">E. coli</italic>. (<xref rid="SuF1" ref-type="supplementary-material">Table S3</xref>). The accumulation of 4-acetamidobenzoic acid accumulation was also significantly reduced to 0.86 g/L at the end of cultivation (<xref rid="F6" ref-type="fig">Fig. 6H</xref>). This suggests that MgSO<sub>4</sub> may contribute to pABA acetylation. Further investigation into the mechanisms underlying pABA acetylation could provide valuable insights for developing strains of conditions that eliminate 4-acetamidobenzoic acid accumulation completely, leading to even higher pABA production capabilities.</p><fig position="float" fig-type="figure" id="F6"><label>Fig 6</label><caption><p>Results of fed-batch cultivation of GX16BW and GX17BW strains for the production of <italic toggle="yes">para</italic>-aminobenzoic acid (pABA). Graphs illustrate the results for GX16BW (A&#x02013;D) and GX17BW (E&#x02013;H) for (A and E) cell growth, (B and F) <italic toggle="yes">para</italic>-aminobenzoic acid concentration, (C and G) glucose and xylose concentration, and (D and H) 4-acetamidobenzoic acid concentration. Data are presented as means, and error bars indicate the standard deviation from three independent experiments.</p></caption><graphic xlink:href="aem.02468-24.f006" position="float"><alt-text>Growth and metabolic trends over 120 hours. OD&#x02086;&#x02080;&#x02080; and pABA production increase over time. Glucose and xylose consumption correspond with pABA synthesis. 4-acetamidobenzoic acid accumulation rises later in cultivation.</alt-text></graphic></fig></sec><sec id="s3-5"><title>Production of 4APhe in pathway-engineered strains</title><p>Following the success of our strategy with a PYR-emitting biosynthetic pathway, we sought to test the effectiveness of this approach with a pathway that does not release PYR. We selected 4APhe as a target compound, which is synthesized from chorismate without PYR release, in a pathway that is identical to the pABA synthetic pathway up to 4ADC synthesis (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>). Instead, 4-amino-4-deoxy-chorismate mutase (<italic toggle="yes">papB</italic>) and 4-amino-4-deoxyprephenate dehydrogenase (<italic toggle="yes">papC</italic>) convert 4ADC into <italic toggle="yes">p</italic>-aminophenylpyruvate (PAPP), which is subsequently transaminated to yield 4APhe (<xref rid="F1" ref-type="fig">Fig. 1</xref>) (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>). We therefore hypothesized that a more direct influence would be observed on 4APhe production compared to the pABA production. Similar to pABA, 4APhe biosynthesis requires an amino donor; thus, we controlled amino donor availability to optimize 4APhe production by adjusting the initial glucose/xylose concentrations.</p><p>We first constructed the 4APhe-producing strain GX16AW, which harbors the pNE-Ptrc-EcpabAB-SvpapBC (<xref rid="B39" ref-type="bibr">39</xref>) and pSAK-W plasmids. We cultivated these strains in a medium containing 15 g/L glucose and 5 g/L xylose or 10 g/L each of glucose and xylose. After 48 h of cultivation in the high-glucose medium, GX16AW produced 2.48 &#x000b1; 0.39 g/L 4APhe, corresponding to a yield of 0.27 &#x000b1; 0.05 g/g from glucose (<xref rid="F7" ref-type="fig">Fig. 7A and B</xref>). Although the product yields from glucose of 4APhe and pABA were equivalent, cell growth of the GX16AW strain was slightly lower despite similar sugar utilization (<xref rid="F7" ref-type="fig">Fig. 7A, C and D</xref>). This discrepancy may be attributed to the absence of PYR emission during 4APhe biosynthesis, resulting in reduced carbon flux into the TCA cycle. Notably, when 4APhe concentration declined (after 48 h of cultivation), nearly all the available sugars had been depleted, indicating degradation of 4APhe.</p><fig position="float" fig-type="figure" id="F7"><label>Fig 7</label><caption><p>Culture profiles using the GX16AW in M9Y medium containing 15 g/L glucose and 5 g/L xylose (light green circles), 10 g/L each of glucose and xylose (green squares). Graphs illustrate (A) cell growth, (B) 4-amino-phenylalanine (4APhe) concentration, (C) glucose concentration, and (D) xylose concentration. Data are presented as means, and error bars indicate the standard deviation from three independent experiments.</p></caption><graphic xlink:href="aem.02468-24.f007" position="float"><alt-text>Line graphs depict OD&#x02086;&#x02080;&#x02080; and 4APhe production increase, peaking at 48 h before stabilizing. Glucose and xylose depletion correlate with 4APhe synthesis, exhibiting rapid consumption by 72 h.</alt-text></graphic></fig><p>Fed-batch fermentation with simultaneous utilization of glucose and xylose enabled us to improve 4APhe production, with 4.90 g/L of 4APhe produced after 143 h of cultivation (<xref rid="F8" ref-type="fig">Fig. 8</xref>). We further improved 4APhe production by cultivating the GX16AW strain in MgSO<sub>4</sub>-rich medium, similar to the conditions used for enhanced pABA production. However, no significant increase in 4APhe titer was observed (data not shown). While pABA production benefits from the release of PYR, which supports the energy module, 4APhe biosynthesis does not involve PYR release. Thus, the energy module in 4APhe production is not enhanced by MgSO<sub>4</sub>-rich medium, meaning that further optimization of the 4APhe biosynthetic pathway is needed if the titer of 4APhe is to be improved.</p><fig position="float" fig-type="figure" id="F8"><label>Fig 8</label><caption><p>Results of fed-batch cultivation for 4-amino-phenylalanine (4APhe) production using GX16AW. Graphs illustrate (A) cell growth, (B) 4APhe concentration, (C) glucose concentration, and (D) xylose concentration. Data are presented as means, and error bars indicate the standard deviation from three independent experiments.</p></caption><graphic xlink:href="aem.02468-24.f008" position="float"><alt-text>Line graphs plot OD&#x02086;&#x02080;&#x02080; and 4APhe concentration steadily increase over 144 h. Glucose and xylose consumption depict rapid depletion by 72 h, correlating with 4APhe synthesis.</alt-text></graphic></fig></sec><sec id="s3-6"><title>Conclusions</title><p>Our study demonstrates that the co-utilization strategy involving the division of metabolic pathways into distinct production and energy modules is an effective approach for enhancing pABA and 4APhe production in <italic toggle="yes">E. coli</italic>. By optimizing initial sugar concentrations and eliminating pathways responsible for carbon leakage, pABA production is greatly improved to achieve titers of up to 8.22 g/L. To the best of our knowledge, this is the highest pABA production from engineered <italic toggle="yes">E. coli</italic> to date. Furthermore, we achieved high levels of 4APhe production despite the absence of PYR release in the biosynthetic pathway. This provides valuable insights into the development of co-utilization strategies for microbial production of various chemicals, particularly for cases where the biosynthetic pathway requires specific donors such as an amino group. Notably, the co-substrate approach offers a more flexible and rapid means of optimizing biosynthetic pathways compared to extensive genetic modifications. However, we acknowledge that in this study, the impact of substrate ratio on production levels was less pronounced than anticipated. Further investigation is necessary to delineate the relative contributions of co-substrate utilization and metabolic engineering to yield enhancement, as well as to elucidate the broader implications of this approach for microbial chemical biosynthesis.</p></sec></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>We thank Enago for reviewing the English language.</p><p>This work was supported by the Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for JSPS Research Fellow (grant number JP22KJ2279) (to D.N.), the Japan Science and Technology Agency (JST), the Precursory Research for Embryonic Science and Technology (PRESTO) (grant number JPMJPR22N9), Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (B) (grant number JP22H01885), Grant-in-Aid for Scientific Research on Innovative Areas (grant number JP23H04565) (to S.N.), JSPS Grants-in-Aid for Scientific Research (B) (grant number JP22H01880), and the Asahi Glass Foundation (to T.T.).</p><p>D.N.: Conceptualization, investigation, writing&#x02014;original draft. M.K.: Investigation. Y.H.: Investigation. A.M.: Investigation. Y.M.: Data curation, writing&#x02014;review and editing. A.K.: Resources. S.N.: Conceptualization, investigation, writing&#x02014;review and editing, funding acquisition. T.T.: Conceptualization, investigation, writing&#x02014;review and editing, funding acquisition, project administration.</p></ack><sec sec-type="data-availability" id="s4-1"><title>DATA AVAILABILITY</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><sec sec-type="supplementary-material" id="s4-2"><title>SUPPLEMENTAL MATERIAL</title><p specific-use="print-only">The following material is available online at <ext-link xlink:href="https://doi.org/10.1128/aem.02468-24" ext-link-type="uri">https://doi.org/10.1128/aem.02468-24</ext-link>.</p><supplementary-material id="SuF1" position="float" content-type="local-data"><object-id pub-id-type="doi">10.1128/aem.02468-24.SuF1</object-id><label>Supplemental material</label><caption><title>aem.02468-24-s0001.docx</title><p>Figures S1 to S8; Tables S1 to S3.</p></caption><media xlink:href="aem.02468-24-s0001.docx"/></supplementary-material><p specific-use="online-only">ASM does not own the copyrights to Supplemental Material that may be linked to, or accessed through, an article. The authors have granted ASM a non-exclusive, world-wide license to publish the Supplemental Material files. Please contact the corresponding author directly for reuse. </p></sec><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Wu</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Kong</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Huo</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>G</given-names></string-name></person-group>. <year>2014</year>. <article-title>Preparation and properties of waterborne polyurethane/epoxy resin composite coating from anionic terpene-based polyol dispersion</article-title>. <source>Prog Org Coat</source><volume>77</volume>:<fpage>315</fpage>&#x02013;<lpage>321</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.porgcoat.2013.10.005</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Zhan</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Yan</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ran</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Fang</surname>
<given-names>Z</given-names></string-name></person-group>. <year>2020</year>. <article-title>Novel full bio-based phloroglucinol benzoxazine resin: synthesis, curing reaction and thermal stability</article-title>. <source>Polymer (Guildf)</source>
<volume>200</volume>:<fpage>122534</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.polymer.2020.122534</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Averesch</surname>
<given-names>NJH</given-names></string-name>, <string-name><surname>Winter</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Kr&#x000f6;mer</surname>
<given-names>JO</given-names></string-name></person-group>. <year>2016</year>. <article-title>Production of para-aminobenzoic acid from different carbon-sources in engineered Saccharomyces cerevisiae</article-title>. <source>Microb Cell Fact</source>
<volume>15</volume>:<elocation-id>89</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/s12934-016-0485-8</pub-id><pub-id pub-id-type="pmid">27230236</pub-id>
</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Han</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>GB</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>SY</given-names></string-name></person-group>. <year>2020</year>. <article-title>Glutaric acid production by systems metabolic engineering of an <sc>l</sc>-lysine-overproducing Corynebacterium glutamicum</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>117</volume>:<fpage>30328</fpage>&#x02013;<lpage>30334</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.2017483117</pub-id><pub-id pub-id-type="pmid">33199604</pub-id>
</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Kim</surname>
<given-names>DI</given-names></string-name>, <string-name><surname>Chae</surname>
<given-names>TU</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>HU</given-names></string-name>, <string-name><surname>Jang</surname>
<given-names>WD</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>SY</given-names></string-name></person-group>. <year>2021</year>. <article-title>Microbial production of multiple short-chain primary amines via retrobiosynthesis</article-title>. <source>Nat Commun</source>
<volume>12</volume>:<elocation-id>173</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/s41467-020-20423-6</pub-id><pub-id pub-id-type="pmid">33420084</pub-id>
</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Lee</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Song</surname>
<given-names>JE</given-names></string-name>, <string-name><surname>Song</surname>
<given-names>W-S</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>E-J</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>Y-G</given-names></string-name>, <string-name><surname>Jeong</surname>
<given-names>H-J</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>HR</given-names></string-name>, <string-name><surname>Choi</surname>
<given-names>K-Y</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>B-G</given-names></string-name></person-group>. <year>2021</year>. <article-title>Production of Tyrian purple indigoid dye from tryptophan in Escherichia coli</article-title>. <source>Nat Chem Biol</source>
<volume>17</volume>:<fpage>104</fpage>&#x02013;<lpage>112</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41589-020-00684-4</pub-id><pub-id pub-id-type="pmid">33139950</pub-id>
</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Reiter</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Bradley</surname>
<given-names>T</given-names></string-name>, <string-name><surname>B&#x000fc;chel</surname>
<given-names>LA</given-names></string-name>, <string-name><surname>Keller</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Hegedis</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Gassler</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Vorholt</surname>
<given-names>JA</given-names></string-name></person-group>. <year>2024</year>. <article-title>A synthetic methylotrophic Escherichia coli as a chassis for bioproduction from methanol</article-title>. <source>Nat Catal</source>
<volume>7</volume>:<fpage>560</fpage>&#x02013;<lpage>573</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41929-024-01137-0</pub-id><pub-id pub-id-type="pmid">38828428</pub-id>
</mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Liu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zhao</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Gan</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Deng</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Crowe</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Hudson</surname>
<given-names>GA</given-names></string-name>, <string-name><surname>Belcher</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Schmidt</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Astolfi</surname>
<given-names>MCT</given-names></string-name>, <etal>et al.</etal></person-group>. <year>2024</year>. <article-title>Complete biosynthesis of QS-21 in engineered yeast</article-title>. <source>Nature</source>
<volume>629</volume>:<fpage>937</fpage>&#x02013;<lpage>944</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-024-07345-9</pub-id><pub-id pub-id-type="pmid">38720067</pub-id>
</mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Koma</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Yamanaka</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Moriyoshi</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Sakai</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Masuda</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Sato</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Toida</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Ohmoto</surname>
<given-names>T</given-names></string-name></person-group>. <year>2014</year>. <article-title>Production of p-aminobenzoic acid by metabolically engineered Escherichia coli</article-title>. <source>Biosci Biotechnol Biochem</source>
<volume>78</volume>:<fpage>350</fpage>&#x02013;<lpage>357</lpage>. doi:<pub-id pub-id-type="doi">10.1080/09168451.2014.878222</pub-id><pub-id pub-id-type="pmid">25036692</pub-id>
</mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Kubota</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Watanabe</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Suda</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kogure</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Hiraga</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Inui</surname>
<given-names>M</given-names></string-name></person-group>. <year>2016</year>. <article-title>Production of para-aminobenzoate by genetically engineered Corynebacterium glutamicum and non-biological formation of an N-glucosyl byproduct</article-title>. <source>Metab Eng</source>
<volume>38</volume>:<fpage>322</fpage>&#x02013;<lpage>330</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymben.2016.07.010</pub-id><pub-id pub-id-type="pmid">27471069</pub-id>
</mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Mori</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hirata</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Kishida</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mori</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Kondo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Noda</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Tanaka</surname>
<given-names>T</given-names></string-name></person-group>. <year>2023</year>. <article-title>p-Nitrobenzoate production from glucose by utilizing p-aminobenzoate N-oxygenase: AurF</article-title>. <source>Enzyme Microb Technol</source>
<volume>171</volume>:<fpage>110321</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.enzmictec.2023.110321</pub-id><pub-id pub-id-type="pmid">37696175</pub-id>
</mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Mao</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Wei</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Nielsen</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>N</given-names></string-name></person-group>. <year>2024</year>. <article-title>Relieving metabolic burden to improve robustness and bioproduction by industrial microorganisms</article-title>. <source>Biotechnol Adv</source>
<volume>74</volume>:<fpage>108401</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biotechadv.2024.108401</pub-id><pub-id pub-id-type="pmid">38944217</pub-id>
</mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Wu</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Yan</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Jones</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Tang</surname>
<given-names>YJ</given-names></string-name>, <string-name><surname>Fong</surname>
<given-names>SS</given-names></string-name>, <string-name><surname>Koffas</surname>
<given-names>MAG</given-names></string-name></person-group>. <year>2016</year>. <article-title>Metabolic burden: cornerstones in synthetic biology and metabolic engineering applications</article-title>. <source>Trends Biotechnol</source>
<volume>34</volume>:<fpage>652</fpage>&#x02013;<lpage>664</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tibtech.2016.02.010</pub-id><pub-id pub-id-type="pmid">26996613</pub-id>
</mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Lu</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Villada</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>PKH</given-names></string-name></person-group>. <year>2019</year>. <article-title>Modular metabolic engineering for biobased chemical production</article-title>. <source>Trends Biotechnol</source>
<volume>37</volume>:<fpage>152</fpage>&#x02013;<lpage>166</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tibtech.2018.07.003</pub-id><pub-id pub-id-type="pmid">30064888</pub-id>
</mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Orsi</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Claassens</surname>
<given-names>NJ</given-names></string-name>, <string-name><surname>Nikel</surname>
<given-names>PI</given-names></string-name>, <string-name><surname>Lindner</surname>
<given-names>SN</given-names></string-name></person-group>. <year>2021</year>. <article-title>Growth-coupled selection of synthetic modules to accelerate cell factory development</article-title>. <source>Nat Commun</source>
<volume>12</volume>:<elocation-id>5295</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/s41467-021-25665-6</pub-id><pub-id pub-id-type="pmid">34489458</pub-id>
</mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Wirth</surname>
<given-names>NT</given-names></string-name>, <string-name><surname>Gurdo</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Krink</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Vidal-Verd&#x000fa;</surname>
<given-names>&#x000c0;</given-names></string-name>, <string-name><surname>Donati</surname>
<given-names>S</given-names></string-name>, <string-name><surname>F&#x000e9;rnandez-Cabez&#x000f3;n</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Wulff</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Nikel</surname>
<given-names>PI</given-names></string-name></person-group>. <year>2022</year>. <article-title>A synthetic C2 auxotroph of Pseudomonas putida for evolutionary engineering of alternative sugar catabolic routes</article-title>. <source>Metab Eng</source>
<volume>74</volume>:<fpage>83</fpage>&#x02013;<lpage>97</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymben.2022.09.004</pub-id><pub-id pub-id-type="pmid">36155822</pub-id>
</mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Noda</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Mori</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Fujiwara</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Shirai</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Tanaka</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Kondo</surname>
<given-names>A</given-names></string-name></person-group>. <year>2021</year>. <article-title>Reprogramming Escherichia coli pyruvate-forming reaction towards chorismate derivatives production</article-title>. <source>Metab Eng</source>
<volume>67</volume>:<fpage>1</fpage>&#x02013;<lpage>10</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymben.2021.05.005</pub-id><pub-id pub-id-type="pmid">34044138</pub-id>
</mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Fujiwara</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Noda</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Tanaka</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Kondo</surname>
<given-names>A</given-names></string-name></person-group>. <year>2020</year>. <article-title>Metabolic engineering of Escherichia coli for shikimate pathway derivative production from glucose-xylose co-substrate</article-title>. <source>Nat Commun</source>
<volume>11</volume>:<elocation-id>279</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/s41467-019-14024-1</pub-id><pub-id pub-id-type="pmid">31937786</pub-id>
</mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Nonaka</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Hirata</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Kishida</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mori</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Fujiwara</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Kondo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Mori</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Noda</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Tanaka</surname>
<given-names>T</given-names></string-name></person-group>. <year>2024</year>. <article-title>Parallel metabolic pathway engineering for aerobic 1,2-propanediol production in Escherichia coli</article-title>. <source>Biotechnol J</source>
<volume>19</volume>:<elocation-id>e2400210</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/biot.202400210</pub-id><pub-id pub-id-type="pmid">39167552</pub-id>
</mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Jiang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Duan</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Sun</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>S</given-names></string-name></person-group>. <year>2015</year>. <article-title>Multigene editing in the Escherichia coli genome via the CRISPR-Cas9 system</article-title>. <source>Appl Environ Microbiol</source>
<volume>81</volume>:<fpage>2506</fpage>&#x02013;<lpage>2514</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AEM.04023-14</pub-id><pub-id pub-id-type="pmid">25636838</pub-id>
</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Huccetogullari</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Luo</surname>
<given-names>ZW</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>SY</given-names></string-name></person-group>. <year>2019</year>. <article-title>Metabolic engineering of microorganisms for production of aromatic compounds</article-title>. <source>Microb Cell Fact</source>
<volume>18</volume>:<elocation-id>41</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/s12934-019-1090-4</pub-id><pub-id pub-id-type="pmid">30808357</pub-id>
</mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Cao</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Gao</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Su&#x000e1;stegui</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mei</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Shao</surname>
<given-names>Z</given-names></string-name></person-group>. <year>2020</year>. <article-title>Building microbial factories for the production of aromatic amino acid pathway derivatives: from commodity chemicals to plant-sourced natural products</article-title>. <source>Metab Eng</source>
<volume>58</volume>:<fpage>94</fpage>&#x02013;<lpage>132</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymben.2019.08.008</pub-id><pub-id pub-id-type="pmid">31408706</pub-id>
</mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Noda</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Shirai</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Oyama</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kondo</surname>
<given-names>A</given-names></string-name></person-group>. <year>2016</year>. <article-title>Metabolic design of a platform Escherichia coli strain producing various chorismate derivatives</article-title>. <source>Metab Eng</source>
<volume>33</volume>:<fpage>119</fpage>&#x02013;<lpage>129</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymben.2015.11.007</pub-id><pub-id pub-id-type="pmid">26654797</pub-id>
</mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Cabulong</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Valdehuesa</surname>
<given-names>KNG</given-names></string-name>, <string-name><surname>Ramos</surname>
<given-names>KRM</given-names></string-name>, <string-name><surname>Nisola</surname>
<given-names>GM</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>W-K</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>CR</given-names></string-name>, <string-name><surname>Chung</surname>
<given-names>W-J</given-names></string-name></person-group>. <year>2017</year>. <article-title>Enhanced yield of ethylene glycol production from <sc>d</sc>-xylose by pathway optimization in Escherichia coli</article-title>. <source>Enzyme Microb Technol</source>
<volume>97</volume>:<fpage>11</fpage>&#x02013;<lpage>20</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.enzmictec.2016.10.020</pub-id><pub-id pub-id-type="pmid">28010767</pub-id>
</mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Zhu</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Zhong</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Gao</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Tao</surname>
<given-names>Y</given-names></string-name></person-group>. <year>2020</year>. <article-title>Metabolic engineering of Escherichia coli for efficient production of <sc>l</sc>-alanyl-<sc>l</sc>-glutamine</article-title>. <source>Microb Cell Fact</source>
<volume>19</volume>:<elocation-id>129</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/s12934-020-01369-2</pub-id><pub-id pub-id-type="pmid">32527330</pub-id>
</mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Su</surname>
<given-names>HS</given-names></string-name>, <string-name><surname>Lang</surname>
<given-names>BF</given-names></string-name>, <string-name><surname>Newman</surname>
<given-names>EB</given-names></string-name></person-group>. <year>1989</year>. <article-title><sc>l</sc>-serine degradation in Escherichia coli K-12: cloning and sequencing of the sdaA gene</article-title>. <source>J Bacteriol</source>
<volume>171</volume>:<fpage>5095</fpage>&#x02013;<lpage>5102</lpage>. doi:<pub-id pub-id-type="doi">10.1128/jb.171.9.5095-5102.1989</pub-id><pub-id pub-id-type="pmid">2504697</pub-id>
</mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Sawers</surname>
<given-names>G</given-names></string-name></person-group>. <year>2001</year>. <article-title>A novel mechanism controls anaerobic and catabolite regulation of the Escherichia coli tdc operon</article-title>. <source>Mol Microbiol</source>
<volume>39</volume>:<fpage>1285</fpage>&#x02013;<lpage>1298</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2958.2001.02316.x</pub-id><pub-id pub-id-type="pmid">11251844</pub-id>
</mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Shao</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Newman</surname>
<given-names>EB</given-names></string-name></person-group>. <year>1993</year>. <article-title>Sequencing and characterization of the sdaB gene from Escherichia coli K-12</article-title>. <source>Eur J Biochem</source>
<volume>212</volume>:<fpage>777</fpage>&#x02013;<lpage>784</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1432-1033.1993.tb17718.x</pub-id><pub-id pub-id-type="pmid">8385012</pub-id>
</mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Yamamura</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Sayama</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kakikawa</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mori</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Taketo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Kodaira</surname>
<given-names>K</given-names></string-name></person-group>. <year>2000</year>. <article-title>Purification and biochemical properties of an N-hydroxyarylamine O-acetyltransferase from Escherichia coli</article-title>. <source>Biochim Biophys Acta</source>
<volume>1475</volume>:<fpage>10</fpage>&#x02013;<lpage>16</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0304-4165(00)00038-6</pub-id><pub-id pub-id-type="pmid">10806332</pub-id>
</mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Shen</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Sun</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Dong</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Yan</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Yuan</surname>
<given-names>Q</given-names></string-name></person-group>. <year>2021</year>. <article-title>Design and construction of an artificial pathway for biosynthesis of acetaminophen in Escherichia coli</article-title>. <source>Metab Eng</source>
<volume>68</volume>:<fpage>26</fpage>&#x02013;<lpage>33</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymben.2021.09.001</pub-id><pub-id pub-id-type="pmid">34487838</pub-id>
</mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Weinert</surname>
<given-names>BT</given-names></string-name>, <string-name><surname>Iesmantavicius</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Wagner</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Sch&#x000f6;lz</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Gummesson</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Beli</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Nystr&#x000f6;m</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Choudhary</surname>
<given-names>C</given-names></string-name></person-group>. <year>2013</year>. <article-title>Acetyl-phosphate is a critical determinant of lysine acetylation in E. coli</article-title>. <source>Mol Cell</source>
<volume>51</volume>:<fpage>265</fpage>&#x02013;<lpage>272</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.molcel.2013.06.003</pub-id><pub-id pub-id-type="pmid">23830618</pub-id>
</mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Kuhn</surname>
<given-names>ML</given-names></string-name>, <string-name><surname>Zemaitaitis</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>LI</given-names></string-name>, <string-name><surname>Sahu</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Sorensen</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Minasov</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Lima</surname>
<given-names>BP</given-names></string-name>, <string-name><surname>Scholle</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mrksich</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Anderson</surname>
<given-names>WF</given-names></string-name>, <string-name><surname>Gibson</surname>
<given-names>BW</given-names></string-name>, <string-name><surname>Schilling</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Wolfe</surname>
<given-names>AJ</given-names></string-name></person-group>. <year>2014</year>. <article-title>Structural, kinetic and proteomic characterization of acetyl phosphate-dependent bacterial protein acetylation</article-title>. <source>PLoS One</source>
<volume>9</volume>:<elocation-id>e94816</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0094816</pub-id><pub-id pub-id-type="pmid">24756028</pub-id>
</mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Schilling</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Christensen</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Davis</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Sahu</surname>
<given-names>AK</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>LI</given-names></string-name>, <string-name><surname>Walker-Peddakotla</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Sorensen</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Zemaitaitis</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Gibson</surname>
<given-names>BW</given-names></string-name>, <string-name><surname>Wolfe</surname>
<given-names>AJ</given-names></string-name></person-group>. <year>2015</year>. <article-title>Protein acetylation dynamics in response to carbon overflow in Escherichia coli</article-title>. <source>Mol Microbiol</source>
<volume>98</volume>:<fpage>847</fpage>&#x02013;<lpage>863</lpage>. doi:<pub-id pub-id-type="doi">10.1111/mmi.13161</pub-id><pub-id pub-id-type="pmid">26264774</pub-id>
</mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Tokuyama</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Toya</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Matsuda</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Cress</surname>
<given-names>BF</given-names></string-name>, <string-name><surname>Koffas</surname>
<given-names>MAG</given-names></string-name>, <string-name><surname>Shimizu</surname>
<given-names>H</given-names></string-name></person-group>. <year>2019</year>. <article-title>Magnesium starvation improves production of malonyl-CoA-derived metabolites in Escherichia coli</article-title>. <source>Metab Eng</source>
<volume>52</volume>:<fpage>215</fpage>&#x02013;<lpage>223</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymben.2018.12.002</pub-id><pub-id pub-id-type="pmid">30529031</pub-id>
</mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Kawaguchi</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Masuo</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Wakai</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Takaya</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Hasunma</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Kaneko</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Okada</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Sazuka</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Ogino</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Kondo</surname>
<given-names>A</given-names></string-name></person-group>. <year>2023</year>. <article-title>Metabolic engineering for 4-aminophenylalanine production from lignocellulosic biomass by recombinant Escherichia coli</article-title>. <source>RSC Sustain</source>
<volume>1</volume>:<fpage>1043</fpage>&#x02013;<lpage>1054</lpage>. doi:<pub-id pub-id-type="doi">10.1039/D3SU00053B</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Masuo</surname>
<given-names>S</given-names></string-name></person-group>. <year>2024</year>. <article-title>Microbial production of aromatic compounds and synthesis of high-performance bioplastics</article-title>. <source>Biosci Biotechnol Biochem</source>
<volume>88</volume>:<fpage>1247</fpage>&#x02013;<lpage>1253</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bbb/zbae111</pub-id><pub-id pub-id-type="pmid">39113285</pub-id>
</mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Masuo</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kaneko</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Takaya</surname>
<given-names>N</given-names></string-name></person-group>. <year>2016</year>. <article-title>Bacterial fermentation platform for producing artificial aromatic amines</article-title>. <source>Sci Rep</source>
<volume>6</volume>:<elocation-id>25764</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/srep25764</pub-id><pub-id pub-id-type="pmid">27167511</pub-id>
</mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Mohammadi Nargesi</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Trachtmann</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Sprenger</surname>
<given-names>GA</given-names></string-name>, <string-name><surname>Youn</surname>
<given-names>J-W</given-names></string-name></person-group>. <year>2018</year>. <article-title>Production of p-amino-<sc>l</sc>-phenylalanine (<sc>l</sc>-PAPA) from glycerol by metabolic grafting of Escherichia coli</article-title>. <source>Microb Cell Fact</source>
<volume>17</volume>:<elocation-id>149</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/s12934-018-0996-6</pub-id><pub-id pub-id-type="pmid">30241531</pub-id>
</mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="report">
<person-group person-group-type="author"><string-name><surname>Mori</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hirata</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Kishida</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Nonaka</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Kondo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Mori</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Noda</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Tanaka</surname>
<given-names>T</given-names></string-name></person-group>. <year>2024</year>. <article-title>Metabolic engineering of Escherichia coli for 4-nitrophenylalanine production via the 4-aminophenylalanine synthetic pathway</article-title></mixed-citation></ref></ref-list></back></article>